Abbott Has Selected Two Additional Cancer Targets From Celera Genomics For Further Development

Seven Celera Genomics Antigens Now in Research Pipeline with Partners

20-Feb-2006

Celera Genomics Group, an Applera Corporation business, announced that Abbott has selected two Celera antigen targets for further investigation and potential therapeutic development. These are in addition to the two targets Abbott selected for advancement in April 2005 and the two targets announced earlier this month. Abbott now has a total of six targets under investigation from the strategic collaboration established between Celera Genomics and Abbott to discover, develop and commercialize therapies for the treatment of cancer.

Under the terms of the collaboration agreement, a number of protein antigens identified and validated by Celera Genomics are being screened by Abbott. The collaboration encompasses the development of therapeutic antibodies and small molecule drugs against over-expressed cell-surface proteins that have been associated with cancer and identified as therapeutic targets through proteomics research at Celera Genomics. Any of these antigens may be selected for therapeutic development at Abbott. Once this development is complete, Celera Genomics may elect to jointly fund clinical development and commercialization of any resulting therapeutic products and would share any financial returns resulting from commercialization, or alternately be paid milestones and royalties on successful therapies. Abbott has responsibility for the commercialization of jointly funded collaboration products. Celera Genomics retains certain diagnostic rights associated with selected targets.

Other news from the department business & finance

Most read news

More news from our other portals

All FT-IR spectrometer manufacturers at a glance

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world
Topic world Antibodies

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous